Literature DB >> 16935002

Fibronectin impedes "myelin" sheet-directed flow in oligodendrocytes: a role for a beta 1 integrin-mediated PKC signaling pathway in vesicular trafficking.

Zuzana Sisková1, Wia Baron, Hans de Vries, Dick Hoekstra.   

Abstract

Differentiation of oligodendrocytes results in the formation of the myelin sheath, a dramatic morphological alteration that accompanies cell specialization. Here, we demonstrate that changes in the extracellular microenvironment may regulate these morphological changes by altering intracellular vesicular trafficking of myelin sheet-directed proteins. The data reveal that fibronectin, in contrast to laminin-2, decreased membrane-directed transport of endogenous NCAM 140 and the model viral protein VSV G, both proteins normally residing in the myelin membrane. The underlying mechanism relies on an integrin-mediated activation of PKC, which causes stable phosphorylation of MARCKS. As a result, dynamic reorganization of the cortical actin cytoskeleton necessary for the targeting of vesicular trafficking to the myelin sheet is precluded, a prerequisite for morphological differentiation. These data are discussed in the context of the demyelinating disease multiple sclerosis, i.e., that leakage of fibronectin across the blood-brain barrier may impede myelination by interference with intracellular myelin sheet-directed membrane transport.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16935002     DOI: 10.1016/j.mcn.2006.07.001

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  32 in total

1.  A model for sealing plasmalemmal damage in neurons and other eukaryotic cells.

Authors:  Christopher S Spaeth; Elaine A Boydston; Lauren R Figard; Aleksej Zuzek; George D Bittner
Journal:  J Neurosci       Date:  2010-11-24       Impact factor: 6.167

2.  Focal adhesion kinase can play unique and opposing roles in regulating the morphology of differentiating oligodendrocytes.

Authors:  Audrey D Lafrenaye; Babette Fuss
Journal:  J Neurochem       Date:  2010-08-19       Impact factor: 5.372

Review 3.  Polarity development in oligodendrocytes: sorting and trafficking of myelin components.

Authors:  Olaf Maier; Dick Hoekstra; Wia Baron
Journal:  J Mol Neurosci       Date:  2008-01-03       Impact factor: 3.444

Review 4.  Pathophysiology of the brain extracellular matrix: a new target for remyelination.

Authors:  Lorraine W Lau; Rowena Cua; Michael B Keough; Sarah Haylock-Jacobs; V Wee Yong
Journal:  Nat Rev Neurosci       Date:  2013-08-29       Impact factor: 34.870

5.  Differential Regulation of MeCP2 Phosphorylation by Laminin in Oligodendrocytes.

Authors:  Zalak S Parikh; Ashutosh Tripathi; Prakash P Pillai
Journal:  J Mol Neurosci       Date:  2017-06-14       Impact factor: 3.444

6.  Myristoylated Alanine Rich C Kinase Substrate (MARCKS) is essential to β2-integrin dependent responses of equine neutrophils.

Authors:  Mary K Sheats; Kimberly C Pescosolido; Ethan M Hefner; Eui Jae Sung; Kenneth B Adler; Samuel L Jones
Journal:  Vet Immunol Immunopathol       Date:  2014-05-02       Impact factor: 2.046

Review 7.  Glia unglued: how signals from the extracellular matrix regulate the development of myelinating glia.

Authors:  Holly Colognato; Iva D Tzvetanova
Journal:  Dev Neurobiol       Date:  2011-11       Impact factor: 3.964

Review 8.  The influence of microenvironment and extracellular matrix molecules in driving neural stem cell fate within biomaterials.

Authors:  Thomas Wilems; Sangamithra Vardhan; Siliang Wu; Shelly Sakiyama-Elbert
Journal:  Brain Res Bull       Date:  2019-03-18       Impact factor: 4.077

Review 9.  Extracellular cues influencing oligodendrocyte differentiation and (re)myelination.

Authors:  Natalie A Wheeler; Babette Fuss
Journal:  Exp Neurol       Date:  2016-03-23       Impact factor: 5.330

10.  Actomyosin contractility controls cell surface area of oligodendrocytes.

Authors:  Angelika Kippert; Dirk Fitzner; Jonne Helenius; Mikael Simons
Journal:  BMC Cell Biol       Date:  2009-09-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.